📣 Join the IGC Pharma Webcast We invite you to join our upcoming webcast, where we’ll provide updates on IGC Pharma’s latest clinical developments, research initiatives, and strategic priorities. This is a valuable opportunity to hear directly from our leadership team about

Save the date! @IGCPharma to Host Fiscal Year-End 2025 Shareholder Update Call on June 30 at 11:00 am ET. We invite investors and stakeholders to join us for a business update and live Q&A with management. Read the full press release: investor.igcpharma.com/igc-pharma-fis… Dial-in or

@IGCPharma hosted its Fiscal Year-End 2025 Shareholder Update Call yesterday, covering key milestones from the past year and our outlook for the CALMA Trial, AI platform, and pipeline expansion. Replay available here: webcaster4.com/Webcast/Page/2… #igcpharma, #shareholdercall,

A Breakthrough Moment from @IGCPharma: Powered by AI We’re proud to introduce MINT-AD, our proprietary AI platform designed to identify individuals at high risk of Alzheimer’s years before symptoms appear. Built on multimodal data, including brain scans, genomics, and lifestyle,

We’re proud to celebrate the outstanding achievement of Dr. Jagadeesh Rao. He was selected from over 360 nominations across 125 countries. With more than 15 years of contributions to neuroscience, psychiatry, and molecular biology, Dr. Rao continues to shape the future of

IGC Pharma will present 3 scientific posters at the Alzheimer's Association International Conference 2025 (Alzheimer's Association) , highlighting our artificial intelligence achievements in Alzheimer’s research. Our presentations explore how AI can support earlier detection, identify

Honored to have contributed to AAIC 2025 and advanced Alzheimer’s research Our AI and scientific teams, along with our CEO and VP, were in Toronto for this year’s Alzheimer’s Association International Conference. We proudly presented three posters showcasing our latest

New preclinical data on IGC-M3 shows promise in the fight against Alzheimer’s This investigational molecule targets four key drivers of disease progression: amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation in cellular models These findings

Alzheimer’s disease impacts millions worldwide, yet effective treatment options remain limited. At IGC Pharma, we’re working to change that by advancing therapies that address both the symptoms and the root causes of the disease Our pipeline includes IGC-AD1, a proprietary

Shaping the Future of Alzheimer’s Care: Our First Quarter in Review AI-powered tools. Cannabinoid and small molecules platforms. Shaping new ways to understand and address Alzheimer’s disease. Our dedicated team and partners are committed to delivering progress that brings

Expanding CALMA. Advancing Research. Impacting Lives. We’re proud to announce the expansion of our CALMA Phase 2 trial with a new clinical site at Lynn Health Science Institute in Oklahoma City, led by Principal Investigator Dr. Carl Griffin. This milestone helps us reach more

We’re pleased to share that Ascendiant Capital Markets has issued a coverage report on IGC Pharma. The analysis recognizes Q1 progress and points to positive clinical data in 2025 as strong catalysts, raising the price target to $4.50. The full report is available directly from

September is #WorldAlzheimersMonth 55M+ people are affected worldwide, not just by memory loss, but by anxiety, agitation, and emotional changes. At IGC Pharma, we’re driving research with the goal of improving quality of life for patients and caregivers #AlzheimersAwareness

Expanding innovation in neurological care. We’re proud to share that IGC Pharma has received a Notice of Allowance from the USPTO for a novel microdose-based treatment (IGC510) targeting stammering, stuttering, and Tourette’s syndrome. This achievement reflects our commitment

Expanding our reach, strengthening our mission. The CALMA Phase 2 trial is now enrolling patients at Island Health’s Royal Jubilee Hospital in Victoria, British Columbia, marking an important milestone as the study grows across North America. This expansion reinforces our

At IGC Pharma (NYSE American: IGC), we believe that innovation must be both powerful and shareable. We are proud to have been recognized in the NIA PREPARE Challenge for our clean and reusable AI code that advances early Alzheimer’s detection.  This achievement underscores our

What the future of Alzheimer’s care looks like? In a recent IMS Interview spotlight, our CEO and founder Ram Mukunda shared how IGC Pharma is advancing science and innovation to answer that question. He discussed the expansion of our Phase 2 CALMA clinical trial with IGC-AD1,

IGC Pharma has added Ichor Research in Syracuse, New York, led by Principal Investigator Dr. Karl F. Hafner, M.D., as a new site for the Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer’s disease.   For more information about the Syracuse site, please contact Kristen